Table 4 Description of urticaria activity score, weekly itch severity score, and the magnitude of change before and after treatment

1

27

Omalizumab 75-375 mg

24.6 ± 7.4

−17.8^Ϯ

-

-

-

22

Placebo

21.3 ± 7.6

−7.9

-

-

-

2

23

Omalizumab 75 mg

27.3 ± 8.31

−9.8 ± 11.75

-

13.1 ± 3.53

−4.5 ± 5.84

25

Omalizumab 300 mg

27.3 ± 7.19

−19.9 ± 12.38^Ϯ

-

13 ± 3.72

−9.2 ± 5.98^Ϯ

21

Omalizumab 600 mg

26.8 ± 6.98

−14.6 ± 10.17

-

12.6 ± 3.19

−6.5 ± 5.63

21

Placebo

31 ± 7.32

−69 ± 9.84

-

14 ± 4.23

-3.5±5.22

3

82

75 mg omalizumab

30.7 ± 6.9

-

22 (27)

14 ± 3.7

-5.9±6.5

83

150 mg omalizumab

31.4 ± 7.0

-

35 (43)^Ϯ

14.2 ± 4.1

-8.1±6.4^Ϯ

79

300 mg omalizumab

29.5 ± 6.9

-

52 (66)^Ϯ

13.7 ± 3.5

-9.8±6.0^Ϯ

79

Placebo

31 ± 6.6

-

15 (19)

14 ± 3.4

-5.1±5.6

4

252

Omalizumab 300 mg

31.2 ± 6.6

−19 (20.6 a-17.4)*^Ϯ

132 (52)^Ϯ

14 ± 3.6

-8.6 (-9.3 a -7.8)*^Ϯ

84

Placebo

30.2 ± 6.7

−8.5(−11.1 a-5.9)*^Ϯ

10 (12)

13.8 ± 3.6

-4.0 (-5.3 a -2.7)*

5

78

Omalizumab 75 mg

31.7 ± 6.7

−13.82 ± 13.26^Ϯ

20 (26)

14.5 ± 3.6

-6.46±6.14^Ϯ

80

Omalizumab 150 mg

30.3 ± 7.3

−14.44 ± 12.95^Ϯ

32 (40)

14.1 ± 3.8

-6.66±6.28^Ϯ

81

Omalizumab 300 mg

31.3 ± 5.8

−20.75 ± 12.17^Ϯ

42 (52)

14.2 ± 3.3

-9.4±5.73^Ϯ

80

Placebo

31.1 ± 6.7

−8.01 ± 11.47

9 (11)

14.4 ± 3.5

-3.63±5.22